研究单位：[1]Pfizer[2]Dept. Of dermatology &STD, Beijing Friendship Hospital, Capital Medical University[3]Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University[4]Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
The primary objective of this study is to compare the efficacy of CP-690,550 (5 mg BID and 10 mg BID) versus placebo for the reduction in severity of plaque psoriasis after 16 weeks of treatment in Asian subjects with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy.
